Published in Wien Klin Wochenschr on October 03, 2014
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (1993) 5.77
Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation (2012) 4.09
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol (2012) 3.36
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke (2008) 3.14
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology (2012) 2.19
Dabigatran and postmarketing reports of bleeding. N Engl J Med (2013) 2.15
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol (2010) 1.98
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J (2012) 1.84
Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation (2010) 1.64
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood (2012) 1.59
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med (2012) 1.53
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm (2012) 1.44
The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol (2013) 1.42
How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood (2012) 1.31
Evidence-based stroke r-ehabilitation: an expanded guidance document from the european stroke organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack 2008. J Rehabil Med (2009) 1.25
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol (2013) 1.23
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2013) 1.16
Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother (2012) 1.12
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol (2008) 1.08
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost (2011) 1.06
Edoxaban: a new oral direct factor xa inhibitor. Drugs (2011) 1.02
Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood (2011) 0.96
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost (2013) 0.96
Periprocedural bridging management of anticoagulation. Circulation (2012) 0.90
[Dabigatran therapy--perioperative management and interpretation of coagulation tests]. Hamostaseologie (2012) 0.90
The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost (2013) 0.90
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost (2012) 0.89
Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol (2013) 0.89
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract (2013) 0.81
Management of dabigatran-induced bleeding: expert statement. Wien Klin Wochenschr (2013) 0.77
Vitamin K antagonist-associated intracerebral hemorrhage: lessons from a devastating disease in the dawn of the new oral anticoagulants. J Stroke Cerebrovasc Dis (2013) 0.76
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
The risk of recurrent venous thromboembolism in men and women. N Engl J Med (2004) 7.41
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 6.00
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res (2010) 5.08
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
D-dimer levels and risk of recurrent venous thromboembolism. JAMA (2003) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Hydroxyethyl starches: different products--different effects. Anesthesiology (2009) 3.23
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation (2006) 3.08
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J (2008) 3.05
Does carotid stent cell design matter? Stroke (2008) 3.02
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes (2004) 2.89
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med (2016) 2.83
Bivalirudin started during emergency transport for primary PCI. N Engl J Med (2013) 2.80
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost (2007) 2.56
Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care (2010) 2.47
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood (2009) 2.40
Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke (2006) 2.31
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation (2008) 2.20
Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology (2012) 2.19
Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. Ann Neurol (2015) 2.16
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol (2008) 2.10
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation (2004) 2.08
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care (2007) 2.03
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol (2009) 1.98
Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med (2004) 1.98
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation (2005) 1.89
Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88
Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care (2003) 1.88
Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther (2003) 1.85
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Soluble RANKL and risk of nontraumatic fracture. JAMA (2004) 1.83
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2011) 1.81
Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol (2010) 1.81
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res (2009) 1.72
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69
Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg (2009) 1.68
Risk score for peri-interventional complications of carotid artery stenting. Stroke (2006) 1.63
Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol (2005) 1.60
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2014) 1.59
Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2006) 1.58
Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb Haemost (2010) 1.58
Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabetes Care (2008) 1.58
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol (2003) 1.54
A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol (2006) 1.54
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart (2010) 1.53
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke (2013) 1.53
Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J (2009) 1.53
Serum leptin level and the risk of nontraumatic fracture. Am J Med (2004) 1.53
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol (2006) 1.52
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ (2012) 1.51
Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model. Stroke (2004) 1.51
Acute-phase response after stent implantation in the carotid artery: association with 6-month in-stent restenosis. Radiology (2003) 1.51
A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol (2012) 1.51
A mimic of sarcoidosis. Lancet (2007) 1.49
Neopterin, CD4+CD28- lymphocytes and the extent and severity of coronary artery disease. Int J Cardiol (2008) 1.49
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
Hemostasis in cardiac arrest patients treated with mild hypothermia initiated by cold fluids. Resuscitation (2009) 1.49
Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med (2009) 1.48
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 1.48